Company Description

Paradigm Therapeutics is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies to address critical medical needs in the treatment of rare diseases, specifically Epidermolysis Bullosa (EB). Its leading therapy, SD-101 (Zorblisa™), is a topical cream that has completed Phase II and Phase III clinical trials and aims to improve the severe skin effects seen in patients across all EB subtypes.